Legend Biotech Corporation
LEGN
Clasificación en acciones
#4430
Legend Biotech Corporation, through its subsidiaries, operates as a... Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Precio por acción
$19.04
Última sincronización: 2026-10-20
Capitalización bursátil
$3.52B
Cambio (1 día)
2.09%
Cambio (1 año)
-42.06%
País
US
Comercio Legend Biotech Corporation (LEGN)
Categoría
Healthcare
Número de acciones en circulación de Legend Biotech Corporation (LEGN)
Número de acciones en circulación al June 2026: 187.00M
Según los últimos informes financieros y el precio de las acciones de Legend Biotech Corporation, el número actual de acciones en circulación es 187.00M. Al final de December 2023, la empresa tenía 88.04M acciones en circulación. El número de acciones en circulación generalmente se ve afectado por divisiones de acciones y recompras.
Historial de acciones en circulación de Legend Biotech Corporation (LEGN) desde 2017 hasta 2026
Acciones en circulación al final de cada año
| Año | Acciones en circulación | Cambiar |
|---|---|---|
| 2026 (TTM) | 187.00M | 104.54% |
| 2024 | 91.43M | 3.84% |
| 2023 | 88.04M | 10.71% |
| 2022 | 79.52M | 12.91% |
| 2021 | 70.43M | 19.21% |
| 2020 | 59.08M | -10.49% |
| 2019 | 66.00M | 32.01% |
| 2018 | 50.00M | -24.25% |
| 2017 | 66.00M | 0.00% |
Acciones en circulación de empresas similares o competidores
| Empresa | Acciones en circulación | Diferencia | País |
|---|---|---|---|
| 253.90M | 35.78% |
US
|
|
| 396.00M | 111.76% |
US
|
|
| 478.91M | 156.10% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -66.75% |
NL
|
